GlassScriptPhysician profile
Nelson J Owyoung
NPI 1073543641
$7,602.68
in general payments reported to CMS, 2019-2025
33 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $145 · 2021: $1,747 · 2022: $2,035 · 2023: $491 · 2024: $702 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.18 |
| Education | $204.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $1,776.82 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $1,071.05 | 2022-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $679.14 | 2022 | |
| Ucb, INC. | $440.46 | 2019-2025 | Briviact, Nayzilam |
| Astrazeneca Pharmaceuticals LP | $433.51 | 2021-2022 | |
| Mdd US Operations, LLC | $365.23 | 2019-2025 | Gocovri |
| Alexion Pharmaceuticals, INC. | $271.22 | 2019-2025 | Ultomiris |
| Abbvie INC. | $263.98 | 2021 | |
| Livanova USA, INC. | $253.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $232.88 | 2019 | |
| Greenwich Biosciences, INC. | $180.86 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $151.46 | 2019-2022 | |
| Pfizer INC. | $142.02 | 2025 | |
| Acadia Pharmaceuticals INC | $131.18 | 2019 | |
| Lilly USA, LLC | $126.30 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $121.83 | 2021 | |
| Amgen INC. | $118.07 | 2021-2025 | Uplizna |
| Acorda Therapeutics, INC | $106.33 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $75.29 | 2019-2020 | |
| Akcea Therapeutics, INC. | $68.36 | 2020 | |
| Supernus Pharmaceuticals, INC. | $59.87 | 2021-2022 | |
| Eisai INC. | $54.55 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $45.32 | 2024 | Crexont, Rytary |
| Aquestive Therapeutics, INC. | $41.95 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.93 | 2023 | Nuedexta |
| Neurelis, INC. | $25.75 | 2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $25.20 | 2022 | |
| Horizon Therapeutics Plc | $22.04 | 2023 | Uplizna |
| Boston Scientific Corporation | $18.03 | 2019 | |
| Allergan, INC. | $15.27 | 2020 | |
| Sumitomo Pharma America, INC. | $6.41 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Owyoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.